Health ❯ Healthcare ❯ Clinical Research

Efficacy Studies

Phase 3 Trials Randomized Controlled Trials Comparative Effectiveness ESSENCE-TIMI 73b Trial BaxHTN Trial Trial Results HIV Prevention AMT-130 DREAMS-3 Trial Agitation Management Semaglutide Trials TRuE-AD3 Trial Higher Doses Safety Assessments VYVGART Pivotal Trials VER-01 Study LUCENT-3 Study Survival Outcomes HIV-1 Real-World Evidence Tirzepatida in Sleep Apnea Phase 2 Trials DELIVER Trial TRIUMPH-4 Trial STARBORN-1 Trial STEP UP Trial Placebo-Controlled Trials HIV Prevention Strategies CDR-SB Scale Weight Loss Interventions Weight Loss Efficacy ACHIEVE-3 Trial Endpoints in Clinical Trials Statistical Analysis Novo Nordisk Patient Outcomes

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

UBT251 targets GLP‑1, GIP plus glucagon for a mechanistically distinct approach to weight management.

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Zenas' Obexelimab Meets Phase 3 Goals in IgG4-Related Disease With 56% Flare Risk Cut

FDA Approves Vanda’s Nereus, First New Motion Sickness Treatment in Over 40 Years

Dyne’s DMD Drug Hits Primary Endpoint in DELIVER REC, Shows Functional Gains

Protara Reports Strong Interim Phase 2 Results for TARA-002 in Pediatric Lymphatic Malformations

Innovent Says Mazdutide Tops Semaglutide in China Phase 3 Diabetes Trial

EMA Panel Recommends Rejecting Rezurock for Chronic Graft-Versus-Host Disease in EU

J&J Myeloma Trial Stopped Early After Tecvayli–Darzalex Shows PFS and OS Benefit

Cannabis Extract VER-01 Eases Chronic Low Back Pain in Phase 3 Trial

Cochrane Review Finds RSV Vaccines Protect Older Adults and Infants Without Raising Serious Risks

Moonlake Shares Plunge on Mixed Phase 3 Results for Hidradenitis Drug

Phase 3 Trials Show Greater Weight Loss With 7.2 mg Injection and 25 mg Oral Semaglutide

Ionis’ Olezarsen Slashes Triglycerides, Cuts Pancreatitis in Phase 3 Trials